Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a health diagnostics company headquartered in Salt Lake City, Utah, focused on precision pregnancy care and the early prediction of spontaneous preterm birth. News about Sera often centers on its PreTRM® Test, a blood-based biomarker test that provides individualized risk prediction for preterm birth in asymptomatic singleton pregnancies, and on the growing clinical and payer interest in this approach.
On this page, readers can find updates on Sera’s clinical research, including results and publications from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. Company press releases describe how the PRIME randomized controlled trial evaluated the PreTRM Test combined with targeted interventions and reported reductions in very early preterm births, NICU admissions, neonatal complications, and NICU length of stay compared with standard care.
SERA news coverage also includes quarterly financial results, payer and Medicaid pilot initiatives, and commentary on commercial progress for the PreTRM Test. The company has highlighted engagement with Medicaid plans and other organizations in multiple states, as well as presentations at medical and investor conferences where leadership discusses clinical data, health economic analyses, and market adoption efforts.
Investors and healthcare professionals following SERA can use this news feed to review announcements related to leadership appointments, conference presentations, regulatory filings summarized in press releases, and ongoing work to position pregnancy biomarker testing within prenatal care. Bookmark this page to access a consolidated view of Sera Prognostics’ latest press releases, study milestones, and business updates connected to its focus on improving outcomes for mothers and newborns.
Sera Prognostics (NASDAQ: SERA) has appointed Lee Anderson as Chief Commercial Officer to lead its commercial expansion efforts. Anderson brings over 30 years of leadership experience in healthcare, particularly from his successful tenures at Genomic Health and Exact Sciences. His notable achievements include driving nine consecutive years of revenue growth as Vice President of US Oncology Sales and Global Customer Service at Genomic Health. Most recently, Anderson served as Chief Commercial Officer at Biofidelity Inc.
The appointment comes at a crucial time as Sera Prognostics enters its commercial phase following the successful PRIME study. Anderson will focus on expanding adoption and sales of the company's PreTRM Test, leveraging his extensive experience in the biotechnology and diagnostics sector.
Sera Prognostics (NASDAQ: SERA) reported its Q1 2025 financial results, showing revenue of $38,000 compared to zero in Q1 2024. The company posted a net loss of $8.2 million, slightly higher than the $8.1 million loss in the prior year. Total operating expenses increased to $9.3 million from $9.1 million year-over-year.
Following successful PRIME study results, Sera is increasing engagement with payors and pursuing Medicaid opportunities across three states for PreTRM test implementation pilots. The company maintains a strong financial position with $114.2 million in cash and equivalents. R&D expenses decreased 9% to $3.3 million, while SG&A expenses rose to $5.9 million from $5.4 million as the company invests in strategic growth initiatives.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has scheduled its first quarter fiscal year 2025 financial results announcement for May 7, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. Domestic callers can dial (800) 836-8184, while international participants should use (646) 357-8785. A live webcast will be accessible through the company's investor page and will remain archived for one year.
Sera Prognostics (Nasdaq: SERA) announced significant changes to its Board of Directors. Jeff Elliott, currently a senior advisor at Boston Consulting Group and board member of Quanterix , will join the board on March 20, 2025. Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, having previously served as CFO and COO at Exact Sciences.
The company also announced that Ryan Trimble will retire and step down as director on June 30, 2025, after 14 years of service. Additionally, Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders. Both departures are part of the board's ongoing efforts to refresh its composition and expertise.
These changes come at a important time as Sera begins leveraging its recent PRIME study results to build market presence for its PreTRM® test, focusing on improving maternal and neonatal health through pregnancy biomarker information.
Sera Prognostics (NASDAQ: SERA) announced its Q4 and full-year 2024 financial results, highlighting significant clinical achievements and financial developments. The company's PRIME study demonstrated promising results, showing a 25% reduction in neonatal morbidity and mortality index and an 18% reduction in neonatal hospital stay.
Financial highlights include: Q4 2024 revenue of $24,000 (down from $41,000 in Q4 2023), with operating expenses of $9.4 million (up 6% YoY). Full-year 2024 revenue was $77,000 (down from $306,000 in 2023), while net loss improved to $32.9 million (from $36.2 million in 2023).
The company successfully raised $57.5 million through a public offering in February 2025, extending its cash runway through 2028. As of December 31, 2024, Sera held $68.2 million in cash and equivalents. The funds will support US commercial expansion, European market preparation, and additional studies for their PreTRM test.
Sera Prognostics (NASDAQ: SERA), a company focused on improving maternal and neonatal health through pregnancy biomarker information, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for March 19, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key topics. Domestic callers can dial (800) 836-8184, while international participants should use (646) 357-8785. A live webcast will be accessible through the company's investor relations website and will remain archived for one year.
Sera Prognostics (NASDAQ: SERA), known as The Pregnancy Company®, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, from 9:50 a.m. to 10:20 a.m. ET.
President and CEO Zhenya Lindgardt will lead a fireside chat to provide company updates and discuss recent achievements. The company, which specializes in providing innovative pregnancy biomarker information to healthcare professionals and patients, will make the presentation available via live webcast. Interested parties can access both the live presentation and replay through the Investors section of Sera's website at www.seraprognostics.com.
Sera Prognostics (NASDAQ: SERA) has announced the pricing of a $50 million public offering, consisting of 1,250,000 shares of Class A common stock at $4.00 per share and pre-funded warrants to purchase 11,250,000 shares at $3.9999 per warrant. The company has granted underwriters a 30-day option to purchase up to an additional 1,875,000 shares.
The offering, expected to close on February 12, 2025, is being managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets. Sera plans to use the proceeds to expand commercial infrastructure in the United States, prepare for European Union expansion, fund studies for PreTRM test adoption, including a potential FDA submission, and for general corporate purposes.
Sera Prognostics (NASDAQ: SERA) has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase additional shares up to 15% of the total offering. Jefferies, TD Cowen, William Blair are acting as joint book-running managers, with RBC Capital Markets as a bookrunner.
The net proceeds will be used to:
- Expand commercial infrastructure in the United States
- Accelerate European Union expansion preparations
- Fund studies to increase PreTRM test adoption
- Potential FDA submission for broad PreTRM test approval
- General corporate purposes
The offering is subject to market conditions, with no guarantee of completion or final terms. A shelf registration statement on Form S-3 was previously filed and declared effective by the SEC.
Sera Prognostics (NASDAQ: SERA) has announced plans to host a virtual R&D Day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. The event will feature presentations from the company's management team and Dr. Brian Iriye, the principal investigator of the pivotal PRIME study from the High-Risk Pregnancy Center in Las Vegas.
The event will showcase results from the PRIME study (Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs) and include a Q&A session. Participants can join via conference call using US domestic number (800) 836-8184 or international number (646) 357-8785, or through the webcast link available on Sera's website. The webcast recording will be archived on the Investors page for one year.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
